PART B - FEE(S) TRANSMITTAL

and send this form, together 🍾

pplicable fee(s), to: Mail Mail Stop ISSU,

SE Commissioner f atende 1 0 2 P.O. Box 1450 Alexandria, Virginia 22313-1450

TatenGCT 0 2 2007

or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks I through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block I, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block I for any change of address) Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 50446 7590 04/11/2007 Certificate of Malling or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United
States Postal Service with sufficient postage for first class mail in an covelope
addressed to the Mail Stop ISSUE FEE address above, or being facsimile
transmitted to the USPTO (571) 273-2885, on the date indicated below. HOXIE & TSO LLP 374 MILLBURN AVENUE SUTTE 300 E MILLBURN, NJ 07041 Denase Cooper (Depositor's name 10/04/2007 FMETEKI2 00000073 504255 10643627 4 01 FC:1501 1440.00 DA (Date APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO: CONFIRMATION NO. 10/643,627 08/19/2003 Johan Sundelin MPJ93-006CPIDVIACNIDVIM 4459 TITLE OF INVENTION: RECOMBINANT C140 RECEPTOR, ITS AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR APPLIN: TYPE SMALL ENTITY ISSUE FEE DUE **PUBLICATION FEE DUE** PREV. PAID ISSUE FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1400 \$300 \$1700 07/11/2007 EXAMINER ART UNIT CLASS-SUBCLASS GUZO, DAVID 1636 530-324000 . Change of correspondence address or indication of "Fee Address" (37 PR 1.363). 2. For printing on the patent front page, Est Hoxie & Associates (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, Change of correspondence address (or Change of Correspondence address form PTO/SB/122) attached: LLC (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. Thomas "Fee Address" indication (or "Fee Address" Indication form PTO/SB/41; Rsv 03-02 or more recent) attached. Use of a Customer Number is required. LASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. If an assignce is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) Millennium Pharmaceuticals, Inc. Cambridge, Massachusetts lease check the appropriate assignce category or categories (will not be printed on the patent): 🔲 Individual 🚘 Corporation or other private group entity 🔘 Government a. The following fee(s) are submitted: 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) Issue Fee A check is enclosed. Dipublication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order - # of Copies The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number \_\_\_\_\_\_ (enclose an extra copy of this form). Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. □ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). OTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other porty in terest as shown by the records of the United States Patent and Trademark Office.

is collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) application. Confidentiallty is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and muting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete 5 form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. x 1450, Alexandra, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, exandria, Virginia 22313-1450.

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OL-85 (Rev. 07/06) Approved for use through 04/30/2007.

Thomas Hoxie

Authorized Signature

Typed or printed name

OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

32,993

Registration No.

00